Home > Dopamine Receptor & Dopamine Receptor & > Levodopa

Levodopa

左旋多巴

L-DOPA是DOPA的天然形式，是多巴胺前体，可作用于帕金森氏病。

目录号
EY1677
EY1677
纯度
99.19%
99.19%
规格
200 mg
1 g
原价
490
680
售价
490
680
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Levodopa is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), used to treat Parkinson's symptoms.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Mena MA, et al. Neuroreport, 1993, 4(4), 438-440.

    分子式
    C9H11NO4    		 分子量
    197.19    		 CAS号
    59-92-7     		储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    <1 mg/mL    		 Water
    66 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00829439 Angelman Syndrome Drug: Levodopa/Carbidopa (4:1) Boston Children Hospital Phase 1 2009-01-01 2016-09-29
    NCT02741947 Parkinson Disease Drug: Levodopa Benserazide Madopar|Drug: Levodopa Benserazide Teva Italia IRCCS San Raffaele|Agenzia Italiana del Farmaco Phase 4 2014-04-01 2016-04-14
    NCT01026428 Idiopathic Parkinson's Disease Drug: Safinamide + Levodopa|Other: Placebo + Levodopa Newron Phase 1|Phase 2 2009-09-01 2013-03-27
    NCT01281475 Angelman Syndrome Drug: Levodopa|Drug: Placebo Oral Capsule Wen-Hann Tan|Rady Children's Hospital, San Diego|University of California, San Francisco|Baylor College of Medicine|Vanderbilt University|Greenwood Genetic Center|Children's Hospital Medical Center, Cincinnati|Angelman Syndrome Foundation, Inc.|Boston Children Hospital Phase 2|Phase 3 2011-01-01 2016-11-16
    NCT01327261 Healthy Volunteers Drug: Levodopa + benserazide University of Buenos Aires|Laboratorios Phoenix S.A.I.C.y F. Phase 4 2009-08-01 2011-08-03
    NCT01070628 Parkinson's Disease Drug: Stalevo (levodopa/ carbidopa/ entacapone)|Drug: Sinemet (levodopa/carbidopa) Orion Corporation, Orion Pharma Phase 1 2009-12-01 2010-08-12
    NCT02486432 Parkinson's Disease Drug: Levodopa/Carbidopa (Sinemet) NeuroDerm Ltd.|Quotient Clinical Phase 1 2015-04-01 2015-06-28
    NCT00789672 Amblyopia Drug: levodopa/carbidopa|Device: patching|Drug: levodopa/carbidopa Jaeb Center for Health Research|National Eye Institute (NEI) Phase 2 2009-01-01 2016-07-07
    NCT00099268 Parkinson's Disease Drug: Carbidopa/levodopa/entacapone|Drug: Immediate release carbidopa/levodopa Novartis Pharmaceuticals|Orion Corporation, Orion Pharma|Novartis Phase 3 2004-09-01 2012-04-19
    NCT01003002 Parkinson's Disease Drug: Levodopa (delivered intravenously) Oregon Health and Science University|Oregon Clinical and Translational Research Institute 2010-12-01 2016-04-04
    NCT00914134 Parkinson's Disease Drug: Levodopa infusion Helsinki University|Solvay Pharmaceuticals Phase 4 2009-04-01 2011-02-23
    NCT00812760 Retinal Diseases Drug: levodopa Medical University of Vienna Phase 4 2001-10-01 2008-12-19
    NCT02769793 Parkinson Disease Drug: Levodopa dispersible|Drug: Levodopa Seoul National University Hospital|SMG-SNU Boramae Medical Center|Samsung Medical Center Phase 4 2015-06-01 2017-02-21
    NCT00291733 Levodopa Induced Dyskinesia Drug: Levetiracetam|Drug: Placebo 1st Hospital of Social Security Services|UCB Pharma Phase 2 2006-05-01 2007-11-14
    NCT00391898 Parkinson's Disease Drug: Levodopa/carbidopa/entacapone|Drug: Levodopa/carbidopa Novartis Phase 4 2006-10-01 2011-02-16
    NCT01636037 Schizophrenia Drug: levodopa/carbidopa (generic version of Sinemet) Centre for Addiction and Mental Health Phase 2 2012-09-01 2016-03-11
    NCT01883505 Parkinson's Disease Drug: Levodopa and carbidopa|Drug: Placebo NeuroDerm Ltd. Phase 2 2013-12-01 2016-03-31
    NCT01190813 Amblyopia Drug: Levodopa/Carbidopa|Drug: Placebo|Other: Patching Jaeb Center for Health Research|National Eye Institute (NEI) Phase 3 2010-09-01 2016-05-03
    NCT01736176 Advanced Parkinson's Disease Drug: Levodopa-Carbidopa Intestinal Gel|Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|Drug: Levodopa-carbidopa Immediate Release (LC-IR) Tablets AbbVie (prior sponsor, Abbott)|AbbVie Phase 3 2013-03-01 2016-12-16
    NCT00713583 Cocaine Dependence Drug: levodopa|Drug: Placebo The University of Texas Health Science Center, Houston|National Institute on Drug Abuse (NIDA) Phase 2 2008-01-01 2012-03-01
    NCT03023059 Age-related Macular Degeneration Drug: Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet Snyder, Robert W., M.D., Ph.D., P.C. Phase 2 2017-03-01 2017-01-17
    NCT01429077 Nonfluent Aphasia|Stroke Drug: levodopa/carbidopa|Drug: Placebo comparator Rehabilitation Institute of Chicago|U.S. Department of Education Phase 2|Phase 3 2007-10-01 2013-11-27
    NCT02116465 Fasted State Drug: Levodopa Carbidopa immediate release tablets Desitin Arzneimittel GmbH Phase 1 2014-03-01 2014-04-14
    NCT00103805 Healthy Drug: levodopa University Hospital Muenster Phase 4 2003-03-01 2014-05-20

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：